Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors

被引：0
|
作者：
Starodub, Alexander
Gollerkeri, Ashwin
De Savi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
机构：
[1] Christ Hosp, Cincinnati, OH USA
[2] Kymera Therapeut, Watertown, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3171
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 22 - 23
  • [22] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [23] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [24] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Jones, Daniel
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Patel, Priti
    Wang, Min Hui
    Kipps, Thomas J.
    HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
  • [25] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Lawrence, David
    Padmanabhan, Swaminathan
    Takeshita, Kenichi
    Porter, Carl W.
    Goodrich, David W.
    Bernstein, Zale P.
    Wallace, Paul
    Spaner, David
    Mohr, Alice
    Byrne, Catriona
    Hernandez-Ilizaliturri, Francisco
    Chrystal, Cynthia
    Starostik, Petr
    Czuczman, Myron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349
  • [26] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Annunziata, Christina M.
    Kohn, Elise C.
    LoRusso, Patricia
    Houston, Nicole D.
    Coleman, Robert L.
    Buzoianu, Manuela
    Robbie, Gabriel
    Lechleider, Robert
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 77 - 84
  • [27] Phase 1 study of ABBV-155 ± paclitaxel in relapsed/ refractory solid tumors: Results in Japanese patients
    Shimizu, Toshio
    Yonemori, Kan
    Kuboki, Yasutoshi
    Tolcher, Anthony
    Kurokawa, Misaki
    Munasinghe, Wijith
    Phillips, Andrew
    Souers, Andrew
    Johnson, Eric
    He, Lei
    Weitzman, Aaron
    Powderly, John
    Lorusso, Patricia
    Naito, Yoichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1420 - S1420
  • [28] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Christina M. Annunziata
    Elise C. Kohn
    Patricia LoRusso
    Nicole D. Houston
    Robert L. Coleman
    Manuela Buzoianu
    Gabriel Robbie
    Robert Lechleider
    Investigational New Drugs, 2013, 31 : 77 - 84
  • [29] A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors
    Cash, Thomas
    Jonus, Hunter C.
    Tsvetkova, Maya
    Beumer, Jan H.
    Sadanand, Arhanti
    Lee, Jasmine Y. Y.
    Henry, Curtis J.
    Aguilera, Dolly
    Harvey, R. Donald
    Goldsmith, Kelly C.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
  • [30] Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Awan, Farrukh T.
    Heerema, Nyla A.
    Hoffman, Corinne
    Lozanski, Gerard
    Maddocks, Kami J.
    Moran, Mollie E.
    Reid, Mark A.
    Lucas, Margaret
    Woyach, Jennifer A.
    Whitlow, W. Thomas
    Jones, Jeffrey A.
    Byrd, John C.
    BLOOD, 2018, 132 (15) : 1568 - 1572
12345